Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability".
Publication
, Journal Article
Arad, N; Kroetsch, A; McClellan, M
Published in: Clinical pharmacology and therapeutics
July 2022
Duke Scholars
Published In
Clinical pharmacology and therapeutics
DOI
EISSN
1532-6535
ISSN
0009-9236
Publication Date
July 2022
Volume
112
Issue
1
Start / End Page
25 / 27
Related Subject Headings
- United States
- Pharmacology & Pharmacy
- Medicare
- Humans
- Biosimilar Pharmaceuticals
- Aged
- Adalimumab
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Arad, N., Kroetsch, A., & McClellan, M. (2022). Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability". Clinical Pharmacology and Therapeutics, 112(1), 25–27. https://doi.org/10.1002/cpt.2403
Arad, Nitzan, Adam Kroetsch, and Mark McClellan. “Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability".” Clinical Pharmacology and Therapeutics 112, no. 1 (July 2022): 25–27. https://doi.org/10.1002/cpt.2403.
Arad N, Kroetsch A, McClellan M. Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability". Clinical pharmacology and therapeutics. 2022 Jul;112(1):25–7.
Arad, Nitzan, et al. “Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability".” Clinical Pharmacology and Therapeutics, vol. 112, no. 1, July 2022, pp. 25–27. Epmc, doi:10.1002/cpt.2403.
Arad N, Kroetsch A, McClellan M. Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability". Clinical pharmacology and therapeutics. 2022 Jul;112(1):25–27.
Published In
Clinical pharmacology and therapeutics
DOI
EISSN
1532-6535
ISSN
0009-9236
Publication Date
July 2022
Volume
112
Issue
1
Start / End Page
25 / 27
Related Subject Headings
- United States
- Pharmacology & Pharmacy
- Medicare
- Humans
- Biosimilar Pharmaceuticals
- Aged
- Adalimumab
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences